Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by ImmunoPrecise Antibodies Ltd.
< Previous
1
2
3
Next >
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
Today 8:28 EDT
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
July 24, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
July 21, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
July 16, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 14, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
July 07, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
July 03, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
June 24, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
June 12, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
June 05, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
May 21, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference
May 20, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
May 12, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
April 11, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
March 28, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
March 13, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
March 11, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
March 05, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
February 26, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Announces Key Leadership Changes
February 24, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period
February 20, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
January 27, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
January 22, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
January 17, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Announces Resignation of Chief Financial Officer
December 31, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
December 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Present at The Microcap Conference 2025
December 19, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
December 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
December 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
December 03, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.